Piotr Dąbrowiecki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Piotr Dąbrowiecki has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Mastalerz-Migas
Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland
4 shared publications - Aleksandra Kucharczyk
Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine, 04-141 Warsaw, Poland
4 shared publications - Andrzej Dabrowski
Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
4 shared publications Dorota Brzostek
AstraZeneca Sp z o.o., Warsaw, Poland
4 shared publications- Grażyna Bochenek
Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
4 shared publications - Grzegorz Brożek
Department of Epidemiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
4 shared publications
Latest Publications
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 958
Late Breaking Abstract - Overestimation of asthma control and misperception of short-acting ß2-agonists (SABA) use among physicians in Poland
Background: Poland does not currently have a national asthma management policy. Although the global GINA guidelines are regularly translated, they may be adopted differently by physicians. Objective: To investigate, if the real-life assessment of asthma control in Poland meets global management standards. Methods: In total, 70 alergists, 80 pulmonologists and 103 GPs participated in the study. All physicians responded to a qualitative questionnaire and delivered diaries (assessment and decisions) of the 10 consecutive asthma patients. The level of asthma control assessed subjectively by the physicians was matched with the patient-reported symptoms according to the GINA guidelines. We also asked physicians about the frequency of short-acting ß2-agonists (SABA) use as a sign of poor asthma control. Results: Data obtained from 253 physicians and 2,482 patients showed, that only 59.1% allergists, 44.1% pulmonologists and 44.1% GPs correctly assessed the level of asthma control according to the GINA guidelines (p=0.05, chi²-test). In terms of the GINA guidelines for SABA consumption, only 27% of allergists, 15% pulmonologists and 12% GPs correctly stated the use 1-2 times per week was indicative of controlled asthma. Meanwhile, 41% allergists, 62% pulmonologists and 59% GPs incorrectly assumed the use of 3 or more SABA canisters per year was a sign of controlled asthma. Conclusions: We found low adoption of the GINA guidelines in terms of the assessment of asthma control in Poland, especially regarding SABA overuse. Incorrect assessment of asthma control may lead to sub-optimal treatment decisions.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 958
Late Breaking Abstract - Overestimation of asthma control and misperception of short-acting ß2-agonists (SABA) use among physicians in Poland
Background: Poland does not currently have a national asthma management policy. Although the global GINA guidelines are regularly translated, they may be adopted differently by physicians. Objective: To investigate, if the real-life assessment of asthma control in Poland meets global management standards. Methods: In total, 70 alergists, 80 pulmonologists and 103 GPs participated in the study. All physicians responded to a qualitative questionnaire and delivered diaries (assessment and decisions) of the 10 consecutive asthma patients. The level of asthma control assessed subjectively by the physicians was matched with the patient-reported symptoms according to the GINA guidelines. We also asked physicians about the frequency of short-acting ß2-agonists (SABA) use as a sign of poor asthma control. Results: Data obtained from 253 physicians and 2,482 patients showed, that only 59.1% allergists, 44.1% pulmonologists and 44.1% GPs correctly assessed the level of asthma control according to the GINA guidelines (p=0.05, chi²-test). In terms of the GINA guidelines for SABA consumption, only 27% of allergists, 15% pulmonologists and 12% GPs correctly stated the use 1-2 times per week was indicative of controlled asthma. Meanwhile, 41% allergists, 62% pulmonologists and 59% GPs incorrectly assumed the use of 3 or more SABA canisters per year was a sign of controlled asthma. Conclusions: We found low adoption of the GINA guidelines in terms of the assessment of asthma control in Poland, especially regarding SABA overuse. Incorrect assessment of asthma control may lead to sub-optimal treatment decisions.
- Open Access
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 2638
Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database
Background: Excessive use of short-acting beta2-agonists (SABA) is indicative of poor asthma control, and may increase the risk of exacerbations and asthma-related fatalities. Objectives: This study aimed to determine the factors associated with frequent (≥3 SABA canisters/year) and excessive (≥12 SABA canisters/year) SABA use in a real-life setting and indentify any predictors of asthma exacerbations. Methods: Purchase records from a 1-year period (2018) were retrieved from the nationwide prescription database comprising 5,600 pharmacies across Poland. Of the 91,673 patients (aged 18-64 years) included, there were 5,202 (5.7%) on SABA-only treatment, 5,961 (6.5%) on inhaled corticosteroid (ICS)-mono treatment, and 73,313 (80%) on combined ICS/long-acting beta2 agonist (LABA) therapy. Results: SABA use was most frequent among patients who did not use ICS. Older age (relative risk [RR] 1.06, p<0,001) was associated with a higher risk of excessive SABA use; the risk was lower in women (RR, 0.63, p<0,001), in those under secondary care (RR, 0.60, p<0,001), and in those on ICS with (RR, 0.52, p<0,001) or without (RR, 0.41, p<0,001) LABA therapy. Excessive SABA use was the strongest predictor of asthma exacerbations (RR, 3.23, p<0,001); however older patients (RR, 1.34, p<0,001), women (RR, 1.14, p=0,001), those under secondary care (RR, 1.19, p 100,000 inhabitants (RR, 1.24, p<0,001) were also at risk. Conclusion: Excessive SABA use is most frequent in those who do not use ICS and triples the risk of asthma exacerbation.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 2638
Open AccessPredictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database
Background: Excessive use of short-acting beta2-agonists (SABA) is indicative of poor asthma control, and may increase the risk of exacerbations and asthma-related fatalities. Objectives: This study aimed to determine the factors associated with frequent (≥3 SABA canisters/year) and excessive (≥12 SABA canisters/year) SABA use in a real-life setting and indentify any predictors of asthma exacerbations. Methods: Purchase records from a 1-year period (2018) were retrieved from the nationwide prescription database comprising 5,600 pharmacies across Poland. Of the 91,673 patients (aged 18-64 years) included, there were 5,202 (5.7%) on SABA-only treatment, 5,961 (6.5%) on inhaled corticosteroid (ICS)-mono treatment, and 73,313 (80%) on combined ICS/long-acting beta2 agonist (LABA) therapy. Results: SABA use was most frequent among patients who did not use ICS. Older age (relative risk [RR] 1.06, p<0,001) was associated with a higher risk of excessive SABA use; the risk was lower in women (RR, 0.63, p<0,001), in those under secondary care (RR, 0.60, p<0,001), and in those on ICS with (RR, 0.52, p<0,001) or without (RR, 0.41, p<0,001) LABA therapy. Excessive SABA use was the strongest predictor of asthma exacerbations (RR, 3.23, p<0,001); however older patients (RR, 1.34, p<0,001), women (RR, 1.14, p=0,001), those under secondary care (RR, 1.19, p 100,000 inhabitants (RR, 1.24, p<0,001) were also at risk. Conclusion: Excessive SABA use is most frequent in those who do not use ICS and triples the risk of asthma exacerbation.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 1411
Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
Background: The Global Initiative for Asthma (GINA) 2019 report proposed novel approaches to asthma management, including using combined inhaled corticosteroid-formoterol (ICS/FOR) on an as-needed basis. Patients on ICS/FOR therapy should not require additional short-acting beta2-agonists (SABA) administration. Objective: This study aimed to compare SABA use in patients treated with ICS/FOR to those treated with ICS/salmeterol (ICS/SAL). Methods: We analysed prescription database records from 5,712 pharmacies in Poland, providing information on asthma medications collected by 111,186 patients (aged 12-64 years) (with at least one prescription within six months) in 2018. We included 55,983 patients: 23,375 on ICS/SAL and 32,608 on ICS/FOR. There were 4,248 children (aged 12-17 years), and 51,935 adults (aged 18-64 years). Results: SABA prescriptions were 10% lower in those on ICS/FOR compared to those on ICS/SAL. Meanwhile, the number of prescriptions and total dose of oral corticosteroids (OCS) were similar for patients in ICS/FOR and ICS/SAL. Logistic regression analysis showed the risk of SABA use was 22% lower in those on ICS/FOR than on ICS/SAL (relative risk [RR], 0.78; p<0,001). In adults, the risk of SABA use was also lower in younger patients (RR, 0.93, p<0,001) and men (RR, 1.03, p<0,001). In all subjects, the risk of OCS use was similar for those on ICS/FOR and ICS/SAL, and it was not age-related. Conclusions: Combined ICS/FOR therapy lowers the risk of SABA use in Poland, which supports the new GINA recommendations for asthma management.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 1411
Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
Background: The Global Initiative for Asthma (GINA) 2019 report proposed novel approaches to asthma management, including using combined inhaled corticosteroid-formoterol (ICS/FOR) on an as-needed basis. Patients on ICS/FOR therapy should not require additional short-acting beta2-agonists (SABA) administration. Objective: This study aimed to compare SABA use in patients treated with ICS/FOR to those treated with ICS/salmeterol (ICS/SAL). Methods: We analysed prescription database records from 5,712 pharmacies in Poland, providing information on asthma medications collected by 111,186 patients (aged 12-64 years) (with at least one prescription within six months) in 2018. We included 55,983 patients: 23,375 on ICS/SAL and 32,608 on ICS/FOR. There were 4,248 children (aged 12-17 years), and 51,935 adults (aged 18-64 years). Results: SABA prescriptions were 10% lower in those on ICS/FOR compared to those on ICS/SAL. Meanwhile, the number of prescriptions and total dose of oral corticosteroids (OCS) were similar for patients in ICS/FOR and ICS/SAL. Logistic regression analysis showed the risk of SABA use was 22% lower in those on ICS/FOR than on ICS/SAL (relative risk [RR], 0.78; p<0,001). In adults, the risk of SABA use was also lower in younger patients (RR, 0.93, p<0,001) and men (RR, 1.03, p<0,001). In all subjects, the risk of OCS use was similar for those on ICS/FOR and ICS/SAL, and it was not age-related. Conclusions: Combined ICS/FOR therapy lowers the risk of SABA use in Poland, which supports the new GINA recommendations for asthma management.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4260
Late Breaking Abstract - Patterns of inhaled corticosteroid-formoterol prescriptions in Poland
Background: The Global Initiative for Asthma (GINA) 2019 report proposed novel approaches to asthma management, including using combined inhaled corticosteroid-formoterol (ICS/FOR) on an as-needed basis. This regimen provides the patient with ICS whenever reliever medication is used. Objective: This study aimed to analyze patterns of ICS/FOR prescriptions in a large group of adolescent and adult patients with asthma in Poland. Methods: We analyzed prescription database records from 5,600 pharmacies in Poland, providing information on asthma medications collected by 146,845 patients (with at least one prescription within six months) in 2018. Results: Combined ICS/ long-acting beta2-agonist (LABA) were collected by 69,497 (48%) patients, of which 28,956 (20% of ICS/LABA users) also received short-acting beta2-agonists (SABA). ICS/FOR together with SABA were collected by 10,304 (15% of all ICS/LABA) and without SABA by 18,417 (26.5% of all ICS/LABA) patients, respectively. Among patients prescribed low-dose ICS/FOR for maintenance and reliever therapy, some 6,725 (9.6% of all ICS/LABA) received SABA. Almost 1/3 of low-dose ICS/FOR patients collected fewer than four canisters of these drugs per year. Conclusions: In a large population of Polish patients with asthma, inappropriate use of SABA is common among those using low-dose ICS/FOR as maintenance and reliever therapy. ICS/FOR refill rates are low for some patients, suggesting as-needed use rather than regular maintenance as prescribed.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4260
Late Breaking Abstract - Patterns of inhaled corticosteroid-formoterol prescriptions in Poland
Background: The Global Initiative for Asthma (GINA) 2019 report proposed novel approaches to asthma management, including using combined inhaled corticosteroid-formoterol (ICS/FOR) on an as-needed basis. This regimen provides the patient with ICS whenever reliever medication is used. Objective: This study aimed to analyze patterns of ICS/FOR prescriptions in a large group of adolescent and adult patients with asthma in Poland. Methods: We analyzed prescription database records from 5,600 pharmacies in Poland, providing information on asthma medications collected by 146,845 patients (with at least one prescription within six months) in 2018. Results: Combined ICS/ long-acting beta2-agonist (LABA) were collected by 69,497 (48%) patients, of which 28,956 (20% of ICS/LABA users) also received short-acting beta2-agonists (SABA). ICS/FOR together with SABA were collected by 10,304 (15% of all ICS/LABA) and without SABA by 18,417 (26.5% of all ICS/LABA) patients, respectively. Among patients prescribed low-dose ICS/FOR for maintenance and reliever therapy, some 6,725 (9.6% of all ICS/LABA) received SABA. Almost 1/3 of low-dose ICS/FOR patients collected fewer than four canisters of these drugs per year. Conclusions: In a large population of Polish patients with asthma, inappropriate use of SABA is common among those using low-dose ICS/FOR as maintenance and reliever therapy. ICS/FOR refill rates are low for some patients, suggesting as-needed use rather than regular maintenance as prescribed.
- Open Access
- 13 August 2016
- Published by Springer Nature
- p. 9-17
Ambient PM2.5 Exposure and Mortality Due to Lung Cancer and Cardiopulmonary Diseases in Polish Cities
- 13 August 2016
- Published by Springer Nature
- p. 9-17
Open AccessAmbient PM2.5 Exposure and Mortality Due to Lung Cancer and Cardiopulmonary Diseases in Polish Cities
- 14 October 2014
- Published by Springer Nature
- Vol. 834, 31-38
Traffic-Related Air Pollution and Respiratory Tract Efficiency
High concentrations of air pollutants are characteristic of the vicinity of urban busy roads. Numerous studies have shown that these concentrations are significantly higher in comparison with areas located in a certain distance from roads and especially those in rural areas. Inhabitants living in the proximity of roads are, therefore, likely to be more exposed to adverse effects of air pollutants. On the basis of a study realized in 2008–2012 among nearly 5,000 residents of Warsaw and non-urbanized areas, we used generalized linear regression models (GRM) to identify factors that most significantly influence the variability of respiratory function variables. GRMs combine multiple classes of models and estimation methods such as simple, multiple, or factorial regression, ANOVA, ANCOVA, etc. Therefore, they allow receiving results based also on interactions between the independent variables. This paper presents the results of GRM for the forced expiratory volume in 1 s (FEV1) distribution. They indicate that the variation of FEV1 is associated with personal factors such as age, height, weight, BMI, or gender, as well as with factors related to the place of residence: traffic density, duration, and the floor of residence. The results clearly show that living in the proximity of busy roads in the city is linked with a significant decrease in FEV1 values.
- 14 October 2014
- Published by Springer Nature
- Vol. 834, 31-38
Traffic-Related Air Pollution and Respiratory Tract Efficiency
High concentrations of air pollutants are characteristic of the vicinity of urban busy roads. Numerous studies have shown that these concentrations are significantly higher in comparison with areas located in a certain distance from roads and especially those in rural areas. Inhabitants living in the proximity of roads are, therefore, likely to be more exposed to adverse effects of air pollutants. On the basis of a study realized in 2008–2012 among nearly 5,000 residents of Warsaw and non-urbanized areas, we used generalized linear regression models (GRM) to identify factors that most significantly influence the variability of respiratory function variables. GRMs combine multiple classes of models and estimation methods such as simple, multiple, or factorial regression, ANOVA, ANCOVA, etc. Therefore, they allow receiving results based also on interactions between the independent variables. This paper presents the results of GRM for the forced expiratory volume in 1 s (FEV1) distribution. They indicate that the variation of FEV1 is associated with personal factors such as age, height, weight, BMI, or gender, as well as with factors related to the place of residence: traffic density, duration, and the floor of residence. The results clearly show that living in the proximity of busy roads in the city is linked with a significant decrease in FEV1 values.
- 30 May 2013
- Published by Springer Nature
- Vol. 788, 229-235
Influence of Traffic-Related Air Pollutants on Lung Function
We investigated the influence of traffic-related air pollutants on respiratory function, with a focus on the non-smoking residents of the capital city of Warsaw in Poland, who lived close to busy streets. The results demonstrate that people living in some parts of the city show symptoms of bronchial obstruction over four times more often than those from the control group consisting of the inhabitants of a remote region in eastern Poland, with considerably less air pollution. Using multiple regression models it was shown that, apart from the place of living, the floor the apartment is situated on, the length of residence, allergy, and physical activity are the factors that significantly influence the forced expiratory volume in 1 s (FEV1) and the pseudo-Tiffenau index (FEV1/FVC).
- 30 May 2013
- Published by Springer Nature
- Vol. 788, 229-235
Influence of Traffic-Related Air Pollutants on Lung Function
We investigated the influence of traffic-related air pollutants on respiratory function, with a focus on the non-smoking residents of the capital city of Warsaw in Poland, who lived close to busy streets. The results demonstrate that people living in some parts of the city show symptoms of bronchial obstruction over four times more often than those from the control group consisting of the inhabitants of a remote region in eastern Poland, with considerably less air pollution. Using multiple regression models it was shown that, apart from the place of living, the floor the apartment is situated on, the length of residence, allergy, and physical activity are the factors that significantly influence the forced expiratory volume in 1 s (FEV1) and the pseudo-Tiffenau index (FEV1/FVC).